NorthWest Biotherapeutics Inc (NWBO)

[biosectinvestor]

CRL will be vastly more expensive over time and IP for all aspects of production are much better at the company’s own factory. CRL is not likely to lower their prices and come work at Sawston and there would likely be no reason for NWBO to contemplate a midstream change for no reason. I believe the Advent contract otherwise mirrors the CRL previous contract in all respects other than it is not at the CRL factory. But I don’t think it’s best to do the development work for Flaskworks at another company’s facility. This will be key technology for extending patents for decades.